United Capital Financial Advisers, LLC Biomarin Pharmaceutical Inc Transaction History

United Capital Financial Advisers, LLC

$19.9 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $104,797 - $129,845	-1,408 Reduced 22.89%	4,742 $390,000
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $272,382 - $321,750	3,250 Added 112.07%	6,150 $537,000
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $16,463 - $21,278	216 Added 8.05%	2,900 $279,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $2,381 - $2,645	28 Added 1.05%	2,684 $237,000
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $26,264 - $30,390	-303 Reduced 10.24%	2,656 $230,000
Q1 2023 Aug 14, 2023	BUY	$87.74 - $117.27 $26,585 - $35,532	303 Added 11.41%	2,959 $287,000
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $177,761 - $237,589	-2,026 Reduced 40.64%	2,959 $287,000
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $745,203 - $1 Million	-9,208 Reduced 64.88%	4,985 $515,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $3,450 - $4,071	-42 Reduced 0.3%	14,193 $1.2 Million
Q2 2022 Aug 11, 2022	SELL	$71.48 - $86.85 $26,805 - $32,568	-375 Reduced 2.57%	14,235 $1.18 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $17,827 - $22,245	-240 Reduced 1.62%	14,610 $1.13 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $30,122 - $38,417	-420 Reduced 2.75%	14,850 $1.31 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $7,103 - $8,119	95 Added 0.63%	15,270 $1.18 Million
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $640,551 - $719,273	-8,483 Reduced 35.86%	15,175 $1.27 Million
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $1.08 Million - $1.31 Million	14,391 Added 155.29%	23,658 $1.79 Million
Q4 2020 Feb 17, 2021	SELL	$72.61 - $90.2 $646,156 - $802,689	-8,899 Reduced 48.99%	9,267 $813,000
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $915,120 - $1.67 Million	12,733 Added 234.36%	18,166 $1.38 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $19,092 - $29,812	240 Added 4.62%	5,433 $670,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $103,272 - $140,141	1,447 Added 38.63%	5,193 $439,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $240,755 - $323,542	3,746 New	3,746 $317,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.

Account